Cited by 64Cystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) ResearchTransplantation: Methods and Outcomes

Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis

Open access
Amadori, Anna, Antonelli, Andrea, Balteri, Ilaria, Schreiber, Anja, Bugiani, Massimiliano, De Rose, Virginia·2009·Respiratory Medicine

Abstract

Obstructive lung disease is the major cause of morbidity and mortality in cystic fibrosis (CF). To identify risk factors contributing to FEV(1) decline in CF patients, we carried out a retrospective analysis of clinical and pulmonary function data in a population of CF patients followed up for 5 years and studied the correlation between clinical data and FEV(1) decline. Fifty-one adult CF patients were studied. The FEV(1) decline was related to the following clinical characteristics: CFTR genotype, age, gender, weight, height, age at diagnosis, baseline FEV(1), pancreatic function, presence of airway infection, pancreatic insufficiency and diabetes, number of exacerbations/year and intravenous (i.v.) antibiotic courses/year. Both the number of exacerbations/year and the number of i.v. antibiotic courses/year were strongly related to the FEV(1) decline. Patients with airway infection or with diabetes had significantly lower FEV(1) values during the study as compared with non-infected patients or patients without diabetes; however, both the presence of airway infection or diabetes did not affect the FEV(1) decline. These results suggest that the aggressive treatment of disease exacerbations is crucial for delaying lung function decline in CF.

Integrity signals

Registry

Crossref · 10.1016/j.rmed.2008.09.024

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pulmonary exacerbations are important clinical events associated with disease progression.

    “Pulmonary exacerbations are important clinical events associated with disease progression21-24; elexacaftor–tezacaftor–ivacaftor resulted in a lower rate of pulmonary exacerbations, including severe events leading to hospitalization or treatment with intravenous antibiotics, than placebo.”

Cited by

Sorted by citations

Authors
Amadori, A., Antonelli, A., Balteri, I., Schreiber, A., Bugiani, M., & De Rose, V.
Affiliations
Ospedale San Luigi Gonzaga (IT)
Venue
Respiratory Medicine
Publisher
Elsevier BV
Published
2009-03
Volume
103
Issue
3
Pages
407-413
ISSN
0954-6111 (ISSN-L)
OpenAlex
W2082031673
Cited by
64
References
0
Citations by year
2023: 7 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 7 · 2016: 5 · 2015: 4 · 2014: 5 · 2013: 9 · 2012: 2
FWCI
4.11
Type
journal article
Language
en
Open access
Locations
  • Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords
cystic fibrosis, lung function decline, FEV1, pulmonary exacerbations, intravenous antibiotics, airway infection, CFTR genotype, pancreatic insufficiency, diabetes mellitus, risk factors, adult patients
MeSH terms
Adolescent, Adult, Anti-Bacterial Agents, Cystic Fibrosis, Female, Follow-Up Studies, Forced Expiratory Volume, Humans, Lung, Male, Middle Aged, Exocrine Pancreatic Insufficiency, Prognosis, Recurrence, Regression Analysis, Retrospective Studies, Disease Progression, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review